Department of Pharmacy, Seoul National University Hospital, Seoul, Korea.
J Korean Med Sci. 2010 Mar;25(3):337-41. doi: 10.3346/jkms.2010.25.3.337. Epub 2010 Feb 17.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to interact with the oral anticoagulant warfarin and can cause a serious bleeding complication. In this study, we evaluated the risk factors for international normalized ratio (INR) increase, which is a surrogate marker of bleeding, after addition of an NSAID in a total of 98 patients who used warfarin. Patient age, sex, body mass index, maintenance warfarin dose, baseline INR, coadministered medications, underlying diseases, and liver and kidney functions were evaluated for possible risk factors with INR increase > or =15.0% as the primary end-point. Of the 98 patients, 39 (39.8%) showed an INR elevation of > or =15.0% after adding a NSAID to warfarin therapy. Multivariate analysis showed that high maintenance dose (>40 mg/week) of warfarin (P=0.001), the presence of coadministered medications (P=0.024), the use of meloxicam (P=0.025) and low baseline INR value (P=0.03) were the risk factors for INR increase in respect to NSAID-warfarin interaction. In conclusion, special caution is required when an NSAID is administered to warfarin users if patients are taking warfarin >40 mg/week and other medications interacting with warfarin.
非甾体抗炎药(NSAIDs)已知与口服抗凝药华法林相互作用,并可能导致严重的出血并发症。在这项研究中,我们评估了 98 例使用华法林的患者加用 NSAID 后国际标准化比值(INR)升高的危险因素,INR 升高是出血的替代标志物。评估了患者年龄、性别、体重指数、维持华法林剂量、基线 INR、合用药物、基础疾病以及肝肾功能,以寻找 INR 升高>或=15.0%的可能危险因素作为主要终点。在 98 例患者中,39 例(39.8%)在加用 NSAID 后华法林治疗时 INR 升高>或=15.0%。多变量分析显示,华法林维持剂量高(>40 毫克/周)(P=0.001)、合用药物(P=0.024)、使用美洛昔康(P=0.025)和基线 INR 值低(P=0.03)是 NSAID-华法林相互作用导致 INR 升高的危险因素。总之,如果患者服用华法林>40 毫克/周和其他与华法林相互作用的药物,当给予 NSAID 时,需要特别小心。